While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Zepbound, which earned the nod in November 2023 ... It earned a high-dose (HD) formulation of Eylea in 2023 that decreased ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

In late 2023, the FDA approved Zepbound (tirzepatide), a weekly injection, for weight loss in adults. Unlike other weight-loss injections, Zepbound is the first GLP-1/GIP receptor agonist marketed ...

When I lost weight on WW, I devoted all of my time to the program and I was successful. It was when life got hard that the ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...